GO
Loading...

Amgen Inc

More

  • Stocks wrapped up the session on a high note, with the Dow logging triple-digit gains, after Federal Reserve Chair Janet Yellen said there's still room for the central bank to help the economy. But major index ended relatively flat for the first quarter.

  • FTI Consulting managing director Barbara Ryan provides insight on new drugs showing dramatic improvement in the standard of care for high cholesterol.

  • New class of cholesterol drugs     Monday, 31 Mar 2014 | 1:19 PM ET

    CNBC's Dominic Chu reports on news out about a special new drug that could combat cholesterol.

  • Midday Movers: Amgen, Biogen, Priceline & More Monday, 31 Mar 2014 | 12:18 PM ET

    Take a look at some of Monday's midday movers:

  • Merck, Glaxo end co-pay assistance for Obamacare plans Wednesday, 26 Mar 2014 | 6:26 PM ET

    March 26- Merck and Co Inc and GlaxoSmithKline Plc are not reimbursing drug co-payments for patients who purchase their health insurance through state and federal exchanges set up under the Obamacare program.

  • ZURICH, March 22- Results of two late-stage clinical trials showed high efficacy for Novartis' drug secukinumab when used by patients suffering from moderate-to-severe plaque psoriasis, the Swiss drugmaker said on Saturday.

  • March 21- U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, which is encountering resistance from health insurers and state Medicaid programs. Biogen Idec fell 8 percent, Amgen Inc dropped 3 percent and Celgene Corp lost 3.7 percent.

  • March 21- U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, which is encountering resistance from health insurers and state Medicaid programs. Biogen Idec fell 6 percent, Amgen Inc dropped 2.5 percent and Celgene Corp was down 2 percent.

  • March 14- An experimental Amgen Inc cancer vaccine used to treat advanced melanoma, the deadliest form of skin cancer, proved effective in a late-stage study in shrinking tumors in a way that suggests the drug triggered the intended systemic immune response, according to data presented on Friday.

  • March 7- The U.S. Food and Drug Administration has asked Regeneron Pharmaceuticals Inc and Sanofi SA to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday.

  • March 7- The U.S. Food and Drug Administration has asked Regeneron and Sanofi to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday. U.S.-listed shares of France- based Sanofi were down 1 percent.

  • WASHINGTON, March 4- In a case eagerly watched by publicly traded companies regularly sued by investors, the U.S. Supreme Court will on Wednesday consider overruling a 26- year-old precedent that made it easier for plaintiffs to negotiate large class action settlements.

  • Feb 5- Merck& Co Inc's quarterly profit and sales just missed expectations as its medicines faced competition from cheaper generics, but shares rose 1.5 percent on enthusiasm for newly announced cancer-drug partnerships with rival U.S. companies.

  • Cheaper generics hit Merck fourth-quarter profit Wednesday, 5 Feb 2014 | 8:36 AM ET
    Merck sign in front of the company's building on October 2, 2013 in Summit, New Jersey.

    Merck reported lower sales, just below Wall Street estimates, hurt by competition from cheaper generic medicines.

  • Feb 5- Merck& Co Inc reported quarterly sales that were slightly lower than expected, hurt by competition from cheaper generic medicines, and predicted full-year earnings at the lower end of analysts' expectations. The second-biggest U.S. drugmaker said on Wednesday it earned $781 million, or 26 cents per share, in the fourth quarter.

  • Early movers: DOW, BA, WLP, T, YHOO, EA, & more Wednesday, 29 Jan 2014 | 8:07 AM ET
    Traders on the floor of the New York Stock Exchange on Tuesday.

    Some of the names on the move ahead of the open.

  • Jan 28- Amgen Inc on Tuesday reported a quarterly profit that beat Wall Street forecasts, as it gained full control of its blockbuster rheumatoid arthritis drug Enbrel and saw solid growth in sales of newer products.

  • Jan 28- Amgen Inc on Tuesday reported a forecast-beating quarterly profit, as the profit-sharing agreement on its blockbuster rheumatoid arthritis drug Enbrel became more favorable and on lower taxes.

  • After-hours buzz: Yahoo, AT&T, VMware & More Tuesday, 28 Jan 2014 | 3:30 PM ET

    Companies making headlines after the bell Tuesday:

  • Markets challenge Fed, Apple gets sauced Monday, 27 Jan 2014 | 8:44 PM ET
    Ben Bernanke and Janet Yellen

    Federal Reserve Chairman Ben Bernanke presides over his final meeting this week and already markets are putting his successor to the test.

Most Popular Video

Wednesday, 16 Apr 2014 | 12:00 AM ET

GM unveils new models, hopes for strong sales this year After massive recalls, General Motors is pushing forward with new car models unveiled at the 2014 New York International Auto Show. CNBC's Phil LeBeau explains.

Friday, 11 Apr 2014 | 7:23 AM ET

Former Fed Chairman Ben Bernanke challenges Raghuram Rajan, Reserve Bank of India governor on his views about monetary policies, reports CNBC's Michelle Caruso-Cabrera.

Tuesday, 15 Apr 2014 | 5:40 PM ET

Jonathan Geller, BGR president and editor-in-chief, weighs in on the specifications for Amazon's newly announced 3-D smartphone.